Skip to main content

Iron & Ferritin

Serum ferritin is an iron-storage protein and the most commonly used biomarker for assessing body iron stores — low levels indicate iron deficiency; elevated levels reflect iron overload or inflammation.[1] It is simultaneously an iron-responsive protein and a positive acute-phase reactant, making interpretation highly context-dependent.[2][3]

For the reconstructive urologist and urogynecologist, ferritin sits at the center of preoperative patient blood management (PBM) — iron deficiency anemia (IDA) before radical cystectomy + diversion, complex prolapse, gender-affirming phalloplasty / vaginoplasty, posterior urethroplasty, and any reconstruction with expected blood loss is common and modifiable.

Biochemistry and Regulation​

Ferritin is a large intracellular protein (~ 450 kDa) composed of 24 subunits of two types — H (heavy/heart) and L (light/liver) — forming a hollow sphere capable of storing up to ~ 4,500 iron atoms as ferric oxyhydroxide.[1][4] Synthesis is regulated at two levels:

  • Iron-responsive regulation — Iron-responsive proteins (IRPs) bind iron-responsive elements (IREs) on ferritin mRNA. When intracellular iron is high, IRP binding is suppressed and ferritin translation proceeds; when iron is low, synthesis is suppressed.[1]
  • Inflammatory regulation — Pro-inflammatory cytokines (TNF-α, IL-1β) and oxidative stress upregulate ferritin transcription via NF-κB, independent of iron status. This dual regulation is the fundamental reason ferritin can be misleading in inflammatory states.[3][4]

The small fraction of ferritin circulating in serum is predominantly glycosylated apoferritin (iron-free) and is in equilibrium with tissue iron stores.[1] Marked elevations from hepatocyte damage release non-glycosylated intracellular ferritin, which has a shorter half-life.[1]

Ferritin Thresholds for Iron Deficiency​

Defining the optimal ferritin cutoff for iron deficiency remains an area of active debate, with thresholds varying substantially across guidelines:

ContextFerritin thresholdNotes
WHO (healthy adults)< 15 μg/LHighly specific (~ 99%), poor sensitivity (~ 59%)
General — bone-marrow correlation< 30 μg/LSensitivity 92%, specificity 98%
AGA guideline (IDA workup)< 45 ng/mLSensitivity 85%, specificity 92%
Chronic inflammation (IBD, etc.)< 100 μg/LHigher threshold to account for acute-phase elevation
Heart failure (ESC/AHA)< 100 μg/L (or 100–299 with TSAT < 20%)Defines IDA in HF
CKD (KDIGO)≤ 100 ng/mL with TSAT ≤ 20%Iron therapy indicated
Hemochromatosis screening> 200 μg/L (F) / > 300 μg/L (M)NPV 97% combined with TSAT > 45%

A 2025 NHANES analysis demonstrated the clinical impact of threshold choice: at ferritin ≤ 15 ng/mL, 5.9 million US individuals were classified as having IDA; at the AGA-recommended ≤ 45 ng/mL threshold, 9.2 million — a 56% increase in identified cases.[5]

Interpreting Ferritin in Inflammation​

Because ferritin is a positive acute-phase reactant, coexistent iron deficiency and inflammation can produce falsely normal or elevated ferritin levels, masking true iron depletion.[1][3] Several strategies help:

  • Concurrent CRP measurement — Elevated CRP signals that ferritin may be artificially raised. Higher ferritin cutoffs (≥ 100 μg/L) are recommended in chronic inflammation.[6][7]
  • Transferrin saturation (TSAT) — TSAT < 20% supports iron-restricted erythropoiesis even when ferritin appears "normal".[8]
  • Soluble transferrin receptor (sTfR) and sTfR / log ferritin index — Unlike ferritin, sTfR is largely unaffected by inflammation and rises in true iron deficiency. The sTfR / log ferritin index improves differentiation: a ratio > 2 suggests coexistent iron deficiency. This index increases sensitivity from 41% to 92% compared with ferritin alone.[7][9]

Hyperferritinemia — Differential Diagnosis​

Elevated ferritin requires systematic evaluation; the differential is broad:

  • Iron overload — Hereditary hemochromatosis (HFE C282Y homozygosity), transfusional siderosis, thalassemia syndromes, myelodysplastic syndromes. Isolated iron-overload syndromes rarely exceed ferritin > 15,000 μg/L.[10][11]
  • Inflammation / infection — The most common cause; sepsis, chronic infections, autoimmune disease.[12][13]
  • Liver disease — Hepatocellular damage releases intracellular ferritin; common in alcoholic liver disease, NAFLD / metabolic syndrome, viral hepatitis.[4][10]
  • Malignancy — Hematologic and solid tumors.[10][13]
  • Metabolic syndrome — Increasingly recognized as one of the most common causes of mild-to-moderate hyperferritinemia, often more prevalent than hemochromatosis in venesection cohorts.[14]

Extreme Hyperferritinemia and the Hyperferritinemic Syndromes​

Ferritin > 5,000 μg/L is associated with high ICU-transfer rates (32%) and mortality (28%).[12] Extreme hyperferritinemia (> 25,000 μg/L) is limited to only four causes: HLH/MAS, infections, acute hepatitis, and cytokine release syndromes.[12] A ferritin cutoff of ~ 9,083 μg/L has 92.5% sensitivity and 91.9% specificity for HLH in critically ill patients.[15]

The concept of the "hyperferritinemic syndrome" unifies four conditions — macrophage activation syndrome (MAS), adult-onset Still's disease, catastrophic antiphospholipid syndrome, and septic shock — that share extreme hyperferritinemia, cytokine-storm physiology, and similar therapeutic responses.[16] The framework has been expanded to include severe COVID-19, anti-MDA5 dermatomyositis, and MIS.[17] The 2022 EULAR/ACR points-to-consider recommend checking ferritin in all patients with suspected HLH/MAS; cutoffs differ between pediatric (500–2,000 μg/L) and adult populations (often > 10,000 μg/L).[18]

Ferritin in Heart Failure — An Evolving Definition​

Iron deficiency affects approximately 40% of patients with chronic heart failure and is associated with increased morbidity and mortality independent of anemia.[19] The traditional definition (ferritin < 100 μg/L, or 100–299 with TSAT < 20%) is now being challenged in favor of broader TSAT-anchored definitions.[8] Meta-analyses confirm that IV iron (ferric carboxymaltose or ferric derisomaltose) reduces the composite of cardiovascular death or HF hospitalization by 25% (RR 0.75, 95% CI 0.61–0.93).[19]

Ferritin in CKD​

The KDIGO guideline recommends iron therapy in CKD patients with anemia when ferritin is ≤ 100 ng/mL with TSAT ≤ 20%, and considers iron supplementation up to a ferritin of 500 ng/mL when target hemoglobin has not been achieved on ESA therapy. Profound iron deficiency at ferritin < 30 ng/mL warrants immediate repletion regardless of erythropoietic context.

Reconstructive Relevance​

Preoperative Patient Blood Management​

Universal preoperative anemia screening is standard before major elective reconstruction (radical cystectomy + urinary diversion, complex prolapse, gender-affirming phalloplasty / vaginoplasty, posterior PFUI urethroplasty, RPLND-context reconstruction). The PBM operational thresholds:

  • Ferritin < 30 μg/L — IDA established; treat regardless of inflammation.
  • Ferritin 30–100 μg/L + TSAT < 20% — functional iron deficiency; treat especially when inflammation is present.
  • Ferritin 100–300 μg/L + TSAT < 20% — iron-restricted erythropoiesis; consider IV iron in major surgical preparation when intake-correction window is short.

IV iron is generally preferred over oral in the preoperative window (2–6 weeks before surgery) due to faster repletion, predictable absorption, and tolerability. Ferric carboxymaltose and ferric derisomaltose are the standard agents — both deliver large single doses (1,000–1,500 mg) without staged infusions.

High-Yield Reconstructive Scenarios​

  • Heavy menstrual bleeding / preoperative urogynecology — Pre-hysterectomy / pre-prolapse-repair iron status is one of the most modifiable risk factors for blood loss during complex pelvic-floor reconstruction.
  • Hematuria-driven anemia — Radiation cystitis, bladder cancer with cystectomy planning, vesicovaginal fistula, post-radiation pelvic injury — all routinely present with depleted iron stores that benefit from preoperative repletion.
  • Post-bariatric reconstruction — Especially RYGB and BPD-DS; duodenal bypass impairs iron absorption and creates chronic IDA; ferritin + B12 + folate are standard.
  • Post-cystectomy / ileal-conduit follow-up — Chronic GU blood loss, B12 deficiency from terminal-ileum resection, and metabolic acidosis create an evolving anemia picture; periodic iron studies are part of the diversion-survivorship panel.
  • GLP-1 RA users — Appetite suppression reduces dietary iron intake; check baseline before optimization.
  • AGA-recommended GI workup for unexplained IDA — When IDA is found preoperatively and no GU source is apparent, the AGA guideline mandates bidirectional endoscopy (EGD + colonoscopy) for occult GI malignancy or AVM. Do not assume the cause is urologic.

Hereditary Hemochromatosis Screening​

In patients found incidentally to have ferritin > 200 μg/L (female) / > 300 μg/L (male) with TSAT > 45%, screen for HFE C282Y before attributing to inflammation or NAFLD. The NPV is 97% when both criteria are negative.[20]

See Also​

References​

1. Garcia-Casal MN, Pasricha SR, Martinez RX, Lopez-Perez L, Peña-Rosas JP. "Serum or Plasma Ferritin Concentration as an Index of Iron Deficiency and Overload." Cochrane Database of Systematic Reviews. 2021;5:CD011817. doi:10.1002/14651858.CD011817.pub2

2. Truong J, Naveed K, Beriault D, et al. "The Origin of Ferritin Reference Intervals: A Systematic Review." The Lancet Haematology. 2024;11(7):e530–e539. doi:10.1016/S2352-3026(24)00103-0

3. Mantovani A, Garlanda C. "Humoral Innate Immunity and Acute-Phase Proteins." The New England Journal of Medicine. 2023;388(5):439–452. doi:10.1056/NEJMra2206346

4. Czaja AJ. "Iron disturbances in chronic liver diseases other than haemochromatosis — pathogenic, prognostic, and therapeutic implications." Alimentary Pharmacology & Therapeutics. 2019;49(6):681–701. doi:10.1111/apt.15173

5. Al Ta'ani O, Mayrer BM, Luche NM, et al. "Diagnostic Serum Ferritin Thresholds and Prevalence of Iron Deficiency Anemia." JAMA Internal Medicine. 2025;185(10):1284–1285. doi:10.1001/jamainternmed.2025.2311

6. Camaschella C. "Iron-Deficiency Anemia." The New England Journal of Medicine. 2015;372(19):1832–1843. doi:10.1056/NEJMra1401038

7. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. "Iron Deficiency Anaemia." Lancet. 2016;387(10021):907–916. doi:10.1016/S0140-6736(15)60865-0

8. Weiss G, Goodnough LT. "Anemia of Chronic Disease." The New England Journal of Medicine. 2005;352(10):1011–1023. doi:10.1056/NEJMra041809

9. Cappellini MD, Comin-Colet J, de Francisco A, et al. "Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management." American Journal of Hematology. 2017;92(10):1068–1078. doi:10.1002/ajh.24820

10. Hsu CC, Senussi NH, Fertrin KY, Kowdley KV. "Iron Overload Disorders." Hepatology Communications. 2022;6(8):1842–1854. doi:10.1002/hep4.2012

11. Kowdley KV, Brown KE, Ahn J, Sundaram V. "ACG Clinical Guideline: Hereditary Hemochromatosis." The American Journal of Gastroenterology. 2019;114(8):1202–1218. doi:10.14309/ajg.0000000000000315

12. Fauter M, Mainbourg S, El Jammal T, et al. "Extreme Hyperferritinemia: Causes and Prognosis." Journal of Clinical Medicine. 2022;11(18):5438. doi:10.3390/jcm11185438

13. Liedgens P, Heger JM, Sieg N, et al. "Marked hyperferritinemia in critically ill cancer patients." European Journal of Haematology. 2024;113(4):493–500. doi:10.1111/ejh.14263

14. Le Gac G, Scotet V, Gourlaouen I, et al. "Prevalence of HFE-related haemochromatosis and secondary causes of hyperferritinaemia and their association with iron overload in 1059 French patients treated by venesection." Alimentary Pharmacology & Therapeutics. 2022;55(8):1016–1027. doi:10.1111/apt.16775

15. Lachmann G, Knaak C, Vorderwülbecke G, et al. "Hyperferritinemia in Critically Ill Patients." Critical Care Medicine. 2020;48(4):459–465. doi:10.1097/CCM.0000000000004131

16. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. "The Hyperferritinemic Syndrome: Macrophage Activation Syndrome, Still's Disease, Septic Shock and Catastrophic Antiphospholipid Syndrome." BMC Medicine. 2013;11:185. doi:10.1186/1741-7015-11-185

17. Ruscitti P, Di Cola I, Di Muzio C, et al. "Expanding the Spectrum of the Hyperferritinemic Syndrome." Autoimmunity Reviews. 2022;21(7):103114. doi:10.1016/j.autrev.2022.103114

18. Shakoory B, Geerlinks A, Wilejto M, et al. "The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome." Arthritis & Rheumatology. 2023;75(10):1714–1732. doi:10.1002/art.42636

19. Cheema B, Chokshi A, Orimoloye O, Ardehali H. "Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency: JACC State-of-the-Art Review." Journal of the American College of Cardiology. 2024;83(25):2674–2689. doi:10.1016/j.jacc.2024.03.431

20. Ko CW, Siddique SM, Patel A, et al. "AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia." Gastroenterology. 2020;159(3):1085–1094. doi:10.1053/j.gastro.2020.06.046